ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0846

MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0795

Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0701

miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0613

Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0772

Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins

RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0729

Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0854

Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0582

Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0560

Mortality Burden of Immune-Mediated Inflammatory Diseases (IMID): Race/Ethnicity, Sex, and Geographic Variation in the United States

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0842

mTOR Signaling Pathway Blockade and Rab4 Expression Affects Metabolism of Lupus T Cells

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0603

Multisite Study of the Impact of COVID-19 Era Telemedicine Expansion on Reduction in No-Show Rates

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0687

Musculoskeletal Manifestations in Patients with CD73 Deficiency

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0534

National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0883

Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0774

Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Chronic Antigen-stimulation and an Altered T Cell Receptor Repertoire

RA – Etiology & Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].